Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Ario Takeuchi Last modified date:2019.06.24

Assistant Professor / Surgery / Urology / Kyushu University Hospital


Papers
1. Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol , 25 (2): 112-120, 2018, 2018.02.
2. Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ:, SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1., EMBO Mol Med , 10 (2): 219-238, 2018, 2018.02.
3. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy., Front Oncol , 8: 635, 2018, 2018.12.
4. Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:, Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy., Mol Clin Oncol , 9 (5): 575-581, 2018, 2018.11.
5. Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone., Prostate Int, 6 (3): 104-109,2018, 2018.09.
6. Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:, Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget , 9 (55): 30587-30593, 2018, 2018.07.
7. Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer., Andrologia , 50 (10): e13119, 2018, 2018.12.
8. Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants., Cancer Sci , 109 (10): 3224-3234, 2018, 2018.10.
9. Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:, Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer., Anticancer Res , 38 (7): 4115-4121, 2018, 2018.07.
10. Shiota M, Fujimoto N, Higashijima K, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide., Prostate in press, 2018, 2018.05.
11. Akitake M, Kiyoshima K, Yokomizo A, Shiga K, Koga H, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Yamaguchi A, Eto M:, A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases., Mol Clin Oncol, 8 (6): 785-790, 2018, 2018.06.
12. Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer., J Urol , 199 (3): 734-740, 2018, 2018.03.
13. Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer., Anticancer Res , (10): 5631-5637, 2017, 2017.10.
14. Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I:, Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment., Ann Oncol, 28 (8): 2038-2039, 2017, 2017.08.
15. Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Koga H, Yamaguchi A, Naito S, Eto M:, Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy., Jpn J Clin Oncol, 47 (5): 453-457, 2017, 2017.05.
16. Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Eto M:, The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer., Ann Surg Oncol , 24 (5): 1443-1450, 2017, 2017.05.
17. Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M, Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer., Endocr Relat Cancer , 24 (4): 171-180, 2017, 2017.04.
18. Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, Sasaki T, Nakamura K, Honda H, Eto M, Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer., Jpn J Clin Oncol, 46 (10): 952-957, 2016, 2016.06.
19. Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Eiji Kashiwagi, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism., Prostate Cancer Prostatic Dis , 19 (2): 191-196, 2016, 2016.06.
20. Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S, Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7., J Natl Cancer Inst, 108 (7), 2016, 2016.07.
21. Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M, Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare., 118 (6): 880-884, 2016, 2016.04.
22. Itsumi M, Shiota M, Takeuchi A, Eiji Kashiwagi, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A, Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2., 107 (7): 1022-1028, 2016, 2016.06.
23. Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Eiji Kashiwagi, Kiyoshima K, Inokuchi J, Ryosuke Takahashi, Yokomizo A, Ohara N, Yoshikai Y, Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer., Int Immunopharmacol, 35: 327-331, 2016, 2016.04.
24. Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M, Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells., Oncol Rep , 33 (6): 2947-2953, 2015, 2015.06.
25. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A, Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer., Oncotarget, 6 (11): 9086-9098, 2015, 2015.04.
26. Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer., Anticancer Res, 35 (12): 6925-6932, 2015
, 2015.12.
27. Shiota M, Takeuchi A, Sugimoto M, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml., Anticancer Res, 35 (11): 6137-6145, 2015
, 2015.11.
28. Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchimumi T, Oda Y, Naito S, Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer., Endocr Relat Cance, 22 (6): 889-900, 2015, 2015.12.
29. Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Itsumi M, Inokuchi J, Tatsugami K, Uchiumi T, Naito S, SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy., Eur J Cancer, 51 (14): 1962-1969, 2015, 2015.09.
30. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Ohga S, Nakamura K, Honda H, Naito S, Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy., Oncotarget, 6 (16): 14710-14719, 2015, 2015.06.
31. Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai Y, Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., Transpl Immuno, 32(2):131-9, 2015.03.
32. Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S:, Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer., Support Care Cancer, 22 (12): 3219-3226, 2014, 2014.12.
33. Shiota M, Yokomizo A, Adachi T, Koga H, Yamaguchi A, Imada K, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S:, The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer., Jpn J Clin Oncol, 44 (9): 860-867, 2014, 2014.09.
34. Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S:, Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer., Prostate, 74 (9): 959-969, 2014, 2014.09.
35. Shiota M, Itsumi M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S:, Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer., Prostate, 74 (8): 829-838, 2014, 2014.08.
36. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S:, The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy., J Surg Oncol, 110 (4): 476-481,2014, 2014.04.
37. Shiota M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Song Y, Inokuchi J, Tatsugami K, Uchiumi T, Naito S:, Inhibition of protein kinase c/twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer., Clin Cancer Res , 20 (4): 951-961, 2014, 2014.04.
38. Itsumi M, Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Naito S:, PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells., J Mol Endocrinol, 53 (1): 31-41, 2014, 2014.01.
39. Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A:, Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth., Mol Cell Endocrinol, 384 (1-2): 117-125, 2014, 2014.01.
40. Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S:, Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of twist1, YB-1, and androgen receptor., Prostate, 73 (12): 1336-1344, 2013, 2013.12.
41. Itsumi M, Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Tatsugami K, Inokuchi J, Song Y, Uchiumi T, Naito S., Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer., J Mol Endocrinol, 50 (3): 401-409, 2013, 2013.04.
42. Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Dejima T, Tanaka S, Itsumi M, Eto M, Naito S:, YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α., Cancer Immunol Immunother, 62 (3): 517-527, 2013, 2013.04.